Table 3.
Utility – Details
| Disaggregated Outcomes (Discounted) | Outcomes | Incremental Outcomes | |||
|---|---|---|---|---|---|
| Pegcetacoplan | Eculizumab | Ravulizumab | Pegcetacoplan vs Eculizumab | Pegcetacoplan vs Ravulizumab | |
| Transfusion avoidance AND Hb <10.5 g/dL | 0.706 | 1.812 | 1.812 | −1.106 | −1.106 |
| Transfusion avoidance AND Hb ≥10.5 g/dL | 2.443 | 0.003 | 0.003 | 2.440 | 2.440 |
| Transfusion required | 0.446 | 1.501 | 1.501 | −1.055 | −1.055 |
| Spontaneous remission | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
| Disutility associated with complications | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
| Disutility associated with AEs | −0.202 | −0.246 | −0.246 | 0.044 | 0.044 |
| Disutility associated with IV infusion | −0.080 | −0.267 | −0.025 | 0.187 | −0.055 |
| Total QALYs | 3.313 | 2.803 | 3.045 | 0.510 | 0.268 |
Note: Bold text refers to main titles and important results.